DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)

Currently, many human infectious diseases do not developed effective methods of treatment and prevention. One of the latest successes of biotechnology is the use of adenoviral vectors carrying immunodominant antigens  of various pathogens as genetically engineered vaccines  both  preventive and ther...

Full description

Saved in:
Bibliographic Details
Main Authors: L. V. Cherenova, T. V. Kashtigo, Kh. S. Saiadian, M. M. Shmarov
Format: Article
Language:Russian
Published: St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2017-08-01
Series:Медицинская иммунология
Subjects:
Online Access:https://www.mimmun.ru/mimmun/article/view/1307
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849401598874222592
author L. V. Cherenova
T. V. Kashtigo
Kh. S. Saiadian
M. M. Shmarov
author_facet L. V. Cherenova
T. V. Kashtigo
Kh. S. Saiadian
M. M. Shmarov
author_sort L. V. Cherenova
collection DOAJ
description Currently, many human infectious diseases do not developed effective methods of treatment and prevention. One of the latest successes of biotechnology is the use of adenoviral vectors carrying immunodominant antigens  of various pathogens as genetically engineered vaccines  both  preventive and therapeutic. The use of genetic  engineering technologies allows not  to use in the  manufacture of vaccines  live viruses and  bacteria, reduces  the  time  needed for vaccine  creation and  production of new vaccines.  Adenoviral vectors  naturally penetrate into human cells, causing a rather  long and significant  both humoral and cellular immune response. In the second  part of review, we provide  information about  the ongoing  worldwide  clinical  trials of adenoviral vector-based vaccines against various infectious diseases such as influenza, malaria, Ebola haemorrhagic fever, tuberculosis, hepatitis and  several others, like as to consider selection parameters of volunteers, vaccination schedule, doses of drug administration, results of completed experiments, and preliminary data  on currently ongoing  research.
format Article
id doaj-art-873ea27afa2e4dde939b3d79061df97c
institution Kabale University
issn 1563-0625
2313-741X
language Russian
publishDate 2017-08-01
publisher St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
record_format Article
series Медицинская иммунология
spelling doaj-art-873ea27afa2e4dde939b3d79061df97c2025-08-20T03:37:44ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2017-08-0119432935810.15789/1563-0625-2017-4-329-358930DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)L. V. Cherenova0T. V. Kashtigo1Kh. S. Saiadian2M. M. Shmarov3N. Gamaleya Research Institute of Epidemiology and MicrobiologyN. Gamaleya Research Institute of Epidemiology and MicrobiologyFirst Moscow I. Sechenov State Medical UniversityN. Gamaleya Research Institute of Epidemiology and MicrobiologyCurrently, many human infectious diseases do not developed effective methods of treatment and prevention. One of the latest successes of biotechnology is the use of adenoviral vectors carrying immunodominant antigens  of various pathogens as genetically engineered vaccines  both  preventive and therapeutic. The use of genetic  engineering technologies allows not  to use in the  manufacture of vaccines  live viruses and  bacteria, reduces  the  time  needed for vaccine  creation and  production of new vaccines.  Adenoviral vectors  naturally penetrate into human cells, causing a rather  long and significant  both humoral and cellular immune response. In the second  part of review, we provide  information about  the ongoing  worldwide  clinical  trials of adenoviral vector-based vaccines against various infectious diseases such as influenza, malaria, Ebola haemorrhagic fever, tuberculosis, hepatitis and  several others, like as to consider selection parameters of volunteers, vaccination schedule, doses of drug administration, results of completed experiments, and preliminary data  on currently ongoing  research.https://www.mimmun.ru/mimmun/article/view/1307adenoviral vectorvaccineclinical trialsinfectious diseaseshuman adenoviruschimpanzee adenovirus
spellingShingle L. V. Cherenova
T. V. Kashtigo
Kh. S. Saiadian
M. M. Shmarov
DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
Медицинская иммунология
adenoviral vector
vaccine
clinical trials
infectious diseases
human adenovirus
chimpanzee adenovirus
title DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_full DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_fullStr DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_full_unstemmed DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_short DEVELOPMENT OF VACCINES BASED ON ADENOVIRAL VECTORS: A REVIEW OF FOREIGN CLINICAL STUDIES (PART 2)
title_sort development of vaccines based on adenoviral vectors a review of foreign clinical studies part 2
topic adenoviral vector
vaccine
clinical trials
infectious diseases
human adenovirus
chimpanzee adenovirus
url https://www.mimmun.ru/mimmun/article/view/1307
work_keys_str_mv AT lvcherenova developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart2
AT tvkashtigo developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart2
AT khssaiadian developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart2
AT mmshmarov developmentofvaccinesbasedonadenoviralvectorsareviewofforeignclinicalstudiespart2